KEYNOTE-028: Phase 1b trial of pembrolizumab in PD-L1-positive nasopharyngeal carcinoma - European Medical Journal

Continue

KEYNOTE-028: Phase 1b trial of pembrolizumab in PD-L1-positive nasopharyngeal carcinoma

Oncology

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL, discusses interim results from KEYNOTE-028, a phase 1b clinical trial that was designed to evaluate the antitumour activity and safety of pembrolizumab, an anti-PD-1 antibody, for the treatment of patients with PD-L1-positive nasopharyngeal carcinoma.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given